

Can We Unlock the Potential of TMVR with Ancillary Techniques?

Jamie McCabe, MD

Section Head, Structural Heart Therapies

Director, Center for Innovation in Invasive Cardiology (CIIC)



Beth Israel Lahey Health 

Beth Israel Deaconess
Medical Center



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL



Disclosures

Honoraria / Consulting / Ad Boards:

- Abbott
- Edwards
- Medtronic
- Jena Valve
- Gore
- Alta

Equity / Stock Options:

- Excision Medical
- ConKay Medical
- Septune
- Arcos Medical
- Sparrow Medical
- Nimble Surgical





What keeps patients from mitral replacement?

SURGERY

193 MR Patient Referrals
49% Declined for Surgery

Top Predictors




Predominantly Clinical Factors

TRANSCATHETER

294 patients Screened for TMVR
70% Deemed Ineligible

Ineligibility for Transcatheter Mitral Valve Replacement




Predominantly Anatomic Factors

Adapted from Mirabel M, et al. Eur Heart J. 2007:1358-65


Scotti et al. Canadian Journal of Cardiology. 2023: 590-592




Anatomic Rationale for Exclusion from TMVR




(Below the annulus)




(at the Annulus)




(In the Annulus)






Anatomic Rationale for Exclusion from TMVR




(Below the annulus)



(at the Annulus)




(In the Annulus)






How does a TMVR Obstruct Outflow?



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL



Mechanism of LVOT Obstruction post TMVR



Leaflet covering open cells


Residual LVOT orifice

Vs.



LAMPOON


Laceration of the Anterior Mitral leaflet to Prevent Outflow Obstruction (LAMPOON)



LAMPOON Slice

Posterior mitral leaflet

Ventricle





LVOT

Anterior mitral leaflet



TEE of laceration







LAMPOON FDA-Sponsored IDE Trial

LAMPOON 30 patient IDE:
TMVR in ring or MAC with a Sapien 3
Technical success 100%
0% LVOT Obstruction
93% 30-day survival
No neurologic events

Khan. JACC. 2019




LVOT Velocity 1.6 m/s








The LAMPOON Issue: Not Valve Agnostic


When valve is covered, removing the mitral leaflet is not helpful



SESAME *SE*ptal *S*coring *A*long the *M*idline *E*ndocardium




Myocardial Laceration



Traversing muscle in biplane fluoro


Confirm position / depth




Lacerate with
electrosurgery



TTE imaging of SESAME Laceration




CT Imaging of SESAME Laceration Results



Pre-SESAME (and pre-TAVR)

4 weeks Post-SESAME



248 mm²



Two Human Case Series of SESAME



JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

VOL. 83, NO. 14, 2024

ORIGINAL RESEARCH

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction

Adam B. Greenbaum, MD,^{1,*} Hiroki A. Ueyama, MD,^{2,3*} Patrick T. Gleason, MD,² Jaffar M. Khan, PhD, BM, BCh,^{2,4} Christopher G. Bruce, MB, ChB,^{2,5} Rim N. Halaby, MD,² Toby Rogers, PhD, BM, BCh,^{2,6} George S. Hanzel, MD,² Joe X. Xie, MD,² Iida Byku, MD,² Robert A. Guyton, MD,² Kendra J. Grubb, MD,² John C. Lisko, MD,² Nikoloz Shekhladze, MD,² Errol K. Inci, MD,² Elizabeth A. Grier, MD,² Gaetano Paone, MD,² James M. McCabe, MD,² Robert J. Lederman, MD,^{2,7} Vasilis C. Babaliaros, MD^{2,8}

EuroIntervention

2025;21:e1-e10
published online e-edition xxx2025
DOI: 10.4244/EIJ-D-25-00131

ORIGINAL RESEARCH

SESAME technique: septal scoring along the midline endocardium

James M. McCabe^{1,*}, MD; Shauna Newton¹, MD; Barbara A. Danek¹, MD; David Elison¹, MD; Christine J. Chung¹, MD; Richard Sheu², MD; Srdjan Jelacic², MD; Gregory J. Condos³, MD; Ester Canovas⁴, MD; Adam B. Greenbaum⁴, MD; Vasilis C. Babaliaros⁴, MD; Robert J. Lederman⁵, MD; G. Burkhard Mackensen⁶, MD, PhD

*Corresponding author: University of Washington School of Medicine, 1959 NE Pacific St, Box 356422, Seattle, WA, 98195-6422, USA. E-mail: jamieccabem@u.wa.edu

This paper also includes supplementary data published online at: <https://www.eurointervention.com/doi/10.4244/EIJ-D-25-00131>


Median NeoLVOT gained **146** mm²

TABLE 6 Evolution of Outflow Tracts 43 Days (34-56 Days) After SESAME

	Baseline (n = 51)	Day 30 (n = 51)	Difference ^a	95% CI ^a	P Value ^a	Latest (n = 51)	Difference ^a	95% CI ^a	P Value ^a
LVOT, mm²									
All	288 ± 74	381 ± 126	+93	+135 to +52	<0.001	383 ± 136	+95	+139 to +52	<0.001
HCM	266 ± 69	344 ± 62	+78	+148 to +7.9	0.032	338 ± 71	+72	+146 to 3.2	0.059
Gradient	278 ± 84	403 ± 178	+125	+212 to +37	0.007	416 ± 189	+138	+230 to +45	0.005
No gradient	305 ± 66	373 ± 67	+68	+109 to +26	0.002	368 ± 80	+64	+108 to +19	0.006
Neo-LVOT, mm²									
All	65 ± 64	206 ± 176	+141	+206 to +75	<0.001	214 ± 172	+149	+210 to +89	<0.001
Gradient	39 ± 43	218 ± 229	+179	+298 to +59	0.006	225 ± 231	+186	+307 to +66	0.005
No gradient	86 ± 71	193 ± 99	+106	+167 to +46	0.001	204 ± 104	+118	+176 to +61	<0.001
Skirt-neo-LVOT, mm²									
All	169 ± 24	241 ± 102	+72	+127 to +16	0.015	237 ± 101	+68	+123 to +13	0.018
Gradient	166 ± 27	246 ± 139	+80	+196 to 37	0.2	246 ± 139	+80	+196 to 37	0.2
No gradient	173 ± 21	236 ± 56	+63	+111 to +15	0.016	229 ± 50	+56	+99 to +13	0.015


Values are mean ± SD unless otherwise indicated. ^aWelch 2-sample t-test.
Abbreviations as in Table 1.

Median NeoLVOT gained: **141** mm²





Alcohol vs SESAME for NeoLVOT prior to TMVR



ASA

1. Wong et al. CCI. 2023. 1341-47
2. Belfekih et al. CCI. 2025. 1241-50
3. Wang et al. JACC CI. 2019. 1268-79
4. Gonzalez et al. CCI. 2024. 1023-34


SESAME

1. McCabe et al. EuroIntervention. 2025.
2. Greenbaum et al. JACC. 2024


*No direct head-to-head trials





Anatomic Rationale for Exclusion from TMVR




(Below the annulus)



(at the Annulus)




(In the Annulus)





Atrial Displacement of the TMVR is a 'Big' Concern



Embolization



Prosthesis Choice Increasing



Sapien 3



Commercial M3



Alta Valve (ATLAS Trial)



Intrepid (APOLLO Trial)



Annular dimensions	Annular dimensions	Annular dimensions	Annular dimensions
NeoLVOT	NeoLVOT	Atrial size	NeoLVOT
Skirt NeoLVOT	LV dimensions 1 cm below annulus	% Atrial Contraction	
Calcification distribution	Calcification distribution	Atrial tilt angle	
AML Length	Do Not Allow for Anterior Mitral Leaflet Modification to Improve LVOT		









Annular Reduction by Cinching with TEER In the Commissure (ARCTIC) TMVR

Non-Circumferential MAC

Large Annulus




TEER + TMVR



N = 13 Patients

Median Annular Area	930 mm ²
Median Commissural Length	39.1 mm
Mean # of Clips / Patient	1.5
LAMPOON Performed	5
MVARC Success	11
Paravalvular Leak ≤ 1+	12
Valve Embolization	1
PVL Closure Device Use	2

Condos GJ, et al. *Circ Cardiovasc Interv.* 2024;17:e014224









Circulation: Cardiovascular Interventions
Volume 17, Issue 11, November 2024; Page e014224
<https://doi.org/10.1161/CIRCINTERVENTIONS.124.014224>



STRUCTURAL HEART DISEASE


Transcatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC)

Gregory J. Condos, MD , David Elison, MD, Logan L. Vincent, MD, Rafael Harari, MD, Cristina Sanina, MD , Srdjan Jelacic, MD , Richard Sheu, MD , Christine J. Chung, MD , Gabriel S. Aldea, MD, G. Burkhard Mackensen, MD, PhD , and James M. McCabe, MD 







Example 1



Baseline gradient 11 mmHg



By CTA: 39 x 29 mm valve







Gradient now 26 mmHg



LAMPOON Still Possible




Final Result










Exampe 2: Prior Mantle Radiation – MS



Incomplete Cosgrove band (Felt)





Clips on Either Commissure







LAMPOON Between Clips







Mitral Valve Anchored by Clips




Anatomic Rationale for Exclusion from TMVR




(Below the annulus)



(at the Annulus)




(In the Annulus)






M-TEER: Not Always the Desired Results

CMS Claims Data



Kumar et al. J Interv Cardiol. 2023

Mitraclip Patients Rhineland Heart Failure Network 2010-18



Sugiura et al. Circ Cardiovasc Int. 2022



Last Case Example: Clip Removal



84 year old male living in North Carolina

Multiple heart failure admissions / year for many years. Preserved left ventricular ejection fraction.

On midodrine for persistent hypotension.

Complex medical history




Patient's Surgical / Procedural History




Surgical aortic valve replacement in 2009 for bicuspid aortic stenosis in Boston

Complicated surgery that resulted in a mitral Alfieri Stitch at that time without annuloplasty


Alfieri stitch technique



Persistent mitral valve regurgitation – mitraclip to the mitral valve at a different Boston institution in 2016



His Mitral Valve




Persistent severe regurgitation and now moderate stenosis




Local CT Scan:


1. Clip & stitch in the way
2. Nothing to anchor TMVR to
3. No space in LVOT



Field cut noted across annulus




Arrived Very Sick




Mitral Valve

LV Muscle


Arrived in Seattle with NYHA class IV symptoms
RHC: cardiogenic shock [Cardiac Index 1.8]



SESAME performed
Balloon pump placed



CT Scan 2 days later





CT scan submitted to device manufacturer & FDA who granted emergency use to proceed with TMVR using a trial-based, M3 valve

This still requires re-creating a single mitral valve orifice!






Alfieri Lacerated; AML & PML lacerated off Clip




Clip Removed




8 years in situ





Removing the Clip Removes “Some Leaflet” Too



Hemodynamically tolerated with just an IABP



Mitral Valve Replacement Implanted





Fully-percutaneous Removal Of Non-functional TEER followed by TMVR

JACC: CARDIOVASCULAR INTERVENTIONS

VOL. 17, NO. 4, 2024

© 2024 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER

IMAGES IN INTERVENTION

First-in-Human Percutaneous Excision of a Failed MitraClip Followed by Transcatheter Mitral Valve Replacement



David Elison, MD,^a Gabriel Aldea, MD,^b Srdjan Jelacic, MD,^c Christine J. Chung, MD,^a G. Burkhard Mackensen, MD,^c James M. McCabe, MD^a

JACC: CARDIOVASCULAR INTERVENTIONS

VOL. 17, NO. 13, 2024

© 2024 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER

IMAGES IN INTERVENTION

Hemodynamic Tolerance of TEER Device Extraction Followed by TMVR



Gregory J. Condos, MD,^a David Elison, MD,^a Srdjan Jelacic, MD,^b Richard Sheu, MD,^b Christine J. Chung, MD,^a Gabriel S. Aldea, MD,^c G. Burkhard Mackensen, MD, PhD,^b James M. McCabe, MD^a



Follow Up



Many week hospitalization

Ultimately discharged and flew back to his home in NC

Cr normalized


No repeat hospitalizations

Living independently

Celebrated his 85th birthday and re-applied for his driver's license



18 Months Later in NC




Removed Clips




Case 1

In situ: ~ 2 years



Case 2

In situ: ~ 6 months



Case 3

In situ: ~ 9 years




Case 4

In situ: ~ 5 years



Complexity is the volume of attachments even external to the grip arms



2 year old clip removed by Dave Daniels at Sutter



Conclusions



Anatomic challenges for TMVR remain substantial

Procedural techniques can enable early-stage technologies

Proof of concept techniques are engendering technology iteration to address unmet needs

